CXCR6 Antibody (56811) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # FAB699M
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-reported, Flow Cytometry
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG2B Clone # 56811
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 mouse myeloma cell line transfected with human CXCR6
Met1-Leu342
Accession # O00574
Met1-Leu342
Accession # O00574
Specificity
Stains human CXCR6 transfectants but not irrelevant transfectants.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for CXCR6 Antibody (56811) [DyLight 594]
Application
Recommended Usage
CyTOF-reported
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXCR6
Alternate Names
Bonzo, CD186, CXCR6, STRL33
Gene Symbol
CXCR6
Additional CXCR6 Products
Product Documents for CXCR6 Antibody (56811) [DyLight 594]
Product Specific Notices for CXCR6 Antibody (56811) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...